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Background: Skin tears are traumatic injuries occurring mostly on the extremities due to shearing and friction
forces that separate the epidermis and the dermis from underlying tissues. They are common and occur mostly in
older adults and those taking medications that compromise skin integrity. Pretibial skin tears can develop into leg
ulcers, which require lengthy, expensive treatment to heal. Traumatic injuries are the second most common type of
wounds after pressure ulcers in care homes and are the commonest reason for older adults to require the attention
of a community nurse. Common causes of skin tear injuries are bumping into furniture and other obstacles, using
mobility aids, transfer to/from wheelchairs, getting in and out of bed and falls. No effective preventative measures
currently exist but knee-length, protective socks are now available that contain impact-resistant Kevlar fibres (of the
type used in stab-proof vests) and cushioning layers underneath.
Methods/design: In this pilot parallel group, randomised controlled trial, 90 people at risk of skin-tear injury will be
randomised with equal allocation to receive the intervention or usual care. They will be recruited from care homes
and from the community via general practices and a research volunteer database. Pilot outcomes include recruitment,
eligibility, attrition, ascertainment of injuries and completion of outcome measures. Acceptability of the intervention
and of study participation will be explored using semi-structured interviews. The proposed primary outcome for
the future definitive trial is skin tear-free days. Secondary outcomes are skin tear severity, health status, specific
skin-tears quality of life, capability and fear of falling, measured at baseline and the end of the study and in the
event of a skin tear.
Discussion: The results of this study will be used to inform the development and design of a future randomised
controlled trial to assess the effectiveness and cost-effectiveness of a unique and innovative approach to skin tear
prevention.
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will include publication of quantitative and qualitative findings, and experience of public involvement in peer-reviewed
journals.
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Skin tears are traumatic wounds involving a piece of skin
of varying size being peeled away from underlying tis-
sues either completely or leaving a partial or intact skin
flap. They often occur as a result of rubbing, an abrasion
or a glancing blow to an arm or leg (i.e. from a fall or
being struck or poked obliquely). The most commonly
cited definition of skin tear is that of Payne and Martin:
“A skin tear is a traumatic injury occurring principally
on the extremities of older adults as a result of shearing
or friction forces which separate the epidermis from the
dermis (partial thickness wound) or which separate both
the epidermis and the dermis from underlying structures
(full-thickness wound)” [1]. These are common injuries
[2-6]. Some prevalence data comes from America [7-10]
and more recently from Japan where point prevalence
was 3.9% amongst 410 patients in long-term care [11]
and Australia where two elderly care rehabilitation units
reported 10% [12]. A non-systematic review [9] reported
skin tear incidence between 2.23% and 41.5% and preva-
lence between 6.6% and 23.5% in US care homes. In
Pennsylvania, skin tear reporting became mandatory for
healthcare facilities in 2004 [13], where 88.2% of the
2,807 skin tears were in patients aged over 65 years.
Fourteen percent of an American 120-bed nursing home
population sustained a skin tear per month with an aver-
age of 2.67 tears per resident [14]. A recent wound point
prevalence audit undertaken in North Devon [15] in 16
care homes revealed 195 wounds amongst 115 of 458
residents (25%). Traumatic injuries were the second
most common wound type (37, 19%) after pressure ul-
cers (87, 45%).
Several changes occur in the skin that increase its sus-
ceptibility to traumatic injury [16,17]. These changes are
due to intrinsic ageing and cumulative extrinsic factors
such as photoageing and polypharmacy. They include
vascular atrophy and deterioration of the dermis as col-
lagen and elastin fibres become more sparse and disor-
dered, holding the skin layers together less tightly [18].
Older patients may have also taken oral steroids that
compromise skin integrity and tensile strength and cause
wounds to heal more slowly [19-22]. They may also be
less aware that an injury has occurred due to decreased
pain perception and tactile sensitivity, including diabetic
neuropathy [23]. Fragile skin is most common in people
aged over 75 years. There were 10 million people in this
age group in the UK in 2012, estimated to increase to
17 million in 2032 [24]. Skin tears are unpleasant and
provoke anxiety. They can take a long time to heal and
are prone to infections. Whilst arm injuries are more
common, leg injuries may develop into leg ulcers,
which may require lengthy, expensive treatment [25].
Typical causes of injury leading to skin tears include
wheelchair use, bumping into obstacles, transfers andfalls. There are best practice guidelines for treatment
and preventing infections and ulcers [26]. Prevention
includes staff education, regular assessment, ensuring
clothing does not rub, removing obstacles and moist-
urising the skin [9,27,28].
The novel, knee-length protective socks have a leg sec-
tion woven from Kevlar [29] and elasticated nylon using
the “terry sandwich” method. This gives a flat, slightly
ribbed and stretchy, outer woven base which provides a
tough, cut and abrasion-resistant exterior. There is a
mesh of loops on the inside to provide a cushioning and
impact resistant inner layer. The stretchiness is sufficient
to fit a range of leg diameters within each size without
applying excess pressure, and the socks are held up with
a light elastane soft top band. The foot of the socks is
manufactured from cotton as laceration protection is
not usually required for the feet. Compression hosiery
could be worn underneath if required as the socks are
not designed to offer any compression themselves. Pa-
tients requiring such hosiery are excluded from this
study, however, as this may confound any protective
effects.
Apart from small-scale, uncontrolled testing during
development, there has been no trial of the effectiveness
and cost-effectiveness of this unique and innovative ap-
proach to skin tear prevention. This study will test the
feasibility of running such a trial by addressing areas of
uncertainty within the study protocol.
Method/design
The study is an open, parallel group, randomised con-
trolled study in which participants are randomised to
one of two groups; the intervention group will wear the
protective socks on a daily basis for a period of 16 weeks
whilst the participants in the control group will wear
their usual clothing. See Figure 1 for the patient flow
diagram and Table 1 for the study schedule. The study is
conducted in Devon, UK and aims to recruit 90 partici-
pants, 45 in each arm. The main eligibility criteria for
participants are presented in Table 2. Experiences of
using the socks and/or taking part in the study will be
captured through semi-structured interviews with a pur-
posive sample of participants from both the intervention
and control arms of the study.
The participants will be recruited primarily from
Care Quality Commission registered care homes. Resi-
dents of care homes are widely recognised to be an
under-researched population and at high risk of suffer-
ing skin tears. Depending on recruitment rate of both
homes and participants, up to 45 homes are expected
to take part. In order to augment recruitment, patients
in the community will also be invited to participate.
For logistical reasons, in order to maximise efficiency
in terms of research nurse resource, recruitment efforts
Figure 1 Participant pathway diagram (taken from the Participant Information Sheet).
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sively (Exeter, Exmouth/Sidmouth and Mid Devon,
roughly representing urban, coastal and rural situa-
tions, respectively).
Research question
The research question for the eventual definitive trial will
be “Are protective, Kevlar-woven socks (‘Dermatuff ’) when
compared with care as usual, effective and cost-effective in
providing lower leg skin protection in people at risk of suf-
fering skin tears in terms of their incidence and severity?”
The research question for this pilot is: “Is it feasible to
conduct a trial of ‘Dermatuff ’ protective socks compared
to care as usual in people at risk of suffering skin tears?”Trial objectives
This pilot study is intended to pave the way for a defini-
tive randomised controlled trial assessing the effective-
ness and cost-effectiveness of the new socks in
protecting the lower legs. The aim of this pilot study is
to provide the necessary information for the planning of
the future trial. It will test the feasibility of running such
a trial and provide estimates of recruitment (care homes
and residents, and patients in primary care), trial attri-
tion, completion of questionnaire-based quality of life
measures, baseline scores and standard deviations of
those measures in this population. It will test the feasi-
bility of gathering data on skin tears occurring in care
homes and in the community by research nurses. It will
assess the acceptability of using the protective socks and
Table 1 Tabulated study schedule
Study procedure Set up
(Visit 1)
Baseline/Study Day 0
(Visit 2)
Study Day 1
(the day after consent)
Upon new
injury
Weekly* for 16 weeks Study Day 112 Qualitative data
collection
Identify potentially eligible participants X
Provide Participant Information Sheet X
Informed consent X
Collection of baseline information X
EQ5D-5 L questionnaire X Xc X
ICECAP-O questionnaire X Xc X
FES-I (short) questionnaire X Xc X
Randomisation X
Provision of socks (intervention arm only) X
Wearing of socks (intervention arm only) X –—————————————————————————- > X
Completion of participant diary (intervention arm only) X –—————————————————————————- > X
Photograph wound Xb
Measurement of wound Xb
Wound scoring Xb
Cardiff wound impact schedulea Xc Xd
Adverse event recording X –—————————————————————————- > Xe
Research nurse to visit care home for progress checks X
Patient interviews X
Focus groups X
*Regular contact (visit or telephone), approximately weekly.
aCompleted only by participants who experienced one or more skin tear injuries during their study participation.
bPerformed within one working day following injury.
cPerformed seven days post-injury.
dCompleted on Day 112 by all participants who experienced skin tear injury during the study. In addition, participants who incur an injury during week 16 (Day 106 to 112 inclusive), will also complete the
questionnaire seven days post-injury.
eDay 112 or Day 112 + 1 to 7 days if a skin tear injury occurs during week 16.
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Table 2 Main eligibility criteria (inclusion and exclusion criteria)
Inclusion criteria Exclusion criteria
Resident in a care home or living in the
community and at high risk of skin tears.
Not competent to give informed consent in the opinion of the recruiting nurse.
Aged 65 years or older. Bedbound.
Ambulatory and/or wheelchair user able to take
part in daily activities within a care home or in
the community.
Being treated for current lacerations or ulcers on their legs.
Participant likely to use graduated compression stockings or similar during the intervention period.
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formation about the distribution of the variables to in-
form the sample size calculation for a larger trial. It will
also provide an estimate of the impact of any contamin-
ation (during subsequent interviews).
Specific objectives of this pilot study are therefore:
 To examine the feasibility and acceptability of the
research design, methods and outcome measures
prior to a definitive randomised trial.
 To assess the processes for capturing outcome data.
 To refine the intervention if appropriate through
qualitative work on acceptability.
 To determine recruitment and retention rates (at
care home and resident or community participant
level) to a randomised trial.
 To estimate concordance with the intervention.
 To estimate attrition rates from the study.
 To consider outcome measures which are important
and appropriate for participants for use in the full
trial.
 To evaluate the appropriateness of two systems of
skin tear classification as outcome measures for the
main trial.
 To estimate rates of questionnaire completion.
 To obtain baseline estimates of scores on the
proposed outcome measures in this clinical
population.
 To estimate the variability of outcomes to inform
the sample size of the definitive trial.
 To calculate the sample size required for a definitive
trial.
 To help establish the eligibility criteria for the future
definitive trial (primary care patients, care homes
and residents).
 To estimate the ability to obtain cost and
effectiveness measures.
 To refine the clinical protocol for the use of
protective socks in the full trial.
 To gain further understanding of the practicalities of
running a trial in this population.
 To obtain feedback from nursing homes regarding
the acceptability of the study.Randomisation and blinding
Randomisation will be achieved by means of a Web-
based system created by the Peninsula Clinical Trials
Unit in conjunction with the study statistician. The par-
ticipants will be allocated to the protective socks inter-
vention or to standard care in equal proportions, using
blocks of fixed size to generate the allocation sequence
and achieve balance in the numbers of participants allo-
cated to each group. Variable block sizes were consid-
ered but would provide no advantage since the number
of participants recruited at each care home is likely to be
small. Randomisation will be stratified by geographical
area (i.e. Exeter, Exmouth/Sidmouth and Mid Devon).
The Web-based randomisation system created and
maintained by the clinical trials unit will allow secure ac-
cess via computers or other devices with Internet con-
nectivity. Research nurses will be provided with log-in
details and will perform randomisation from the care
home by smart phone. The system ensures allocation is
concealed prior to performing randomisation. Telephone
randomisation will be available during working hours
(09:00 to 17:00, Monday to Friday inclusive) in the un-
likely event the Web-based service is unavailable.
Blinding will not be possible for participants or re-
search nurses. Blinding is possible for the data analyst,
however, by coding the group allocation in the data file.
Sample size
The target sample size for this pilot trial is 90 partici-
pants. The sample size was based on a group sample of
40 with a 20% inflation to allow for dropout and loss to
follow-up. A sample of 40 in each group was considered
to be adequate for providing robust estimates of skin
tear incidence, skin tear-free days and standard devia-
tions for quality of life and other outcome measures.
Recruitment
Identification of care homes and approach
Care homes will be identified from Care Quality Com-
mission lists with the advice of the local Tissue Viability
Service. The homes will be sent a study brochure to in-
vite them to express an interest in taking part. Staff from
interested homes will be invited to a study event at
Powell et al. Pilot and Feasibility Studies  (2015) 1:12 Page 6 of 13which the study protocol will be explained in a group
setting. All homes expressing interest will be visited by a
research nurse to explain the study in more detail and
confirm willingness to take part. All care homes that
take part will be required to sign a letter of agreement to
acknowledge their understanding of what their involve-
ment entails. At this set-up visit, the research nurse will
provide study-specific training for the staff and will also
identify potentially eligible residents.
The research nurses will not provide any clinical man-
agement; their role is primarily to establish contact with
potential participants and manage the collection of study
data. If, however, during the conduct of the study, the
research nurse notices any condition not related to the
study which, in their professional opinion requires atten-
tion, they have a duty of care to report this to the care
home manager.
Recruitment of care home residents
Potentially eligible residents will be identified to the re-
search nurse by care home staff at the home’s set-up
visit (Visit 1). The research nurse will approach potential
participants, explain the study, show the resident a sam-
ple of the protective socks and leave written information
(i.e. the Research Ethics Committee (REC) approved Par-
ticipant Information Sheet). Care home staff will be pro-
vided with a site file containing essential documents and
contact details (mobile telephone numbers and email ad-
dresses) for the research nurse.
Informed consent
The research nurse will return within a day or two (en-
suring residents have had sufficient time to read, under-
stand and discuss the Participant Information Sheet) to
answer questions and ask whether the potential partici-
pants would like to take part in the study. The research
nurse will be responsible for adjudging the residents’
capacity to provide informed consent, and this will be
achieved through discussion with the resident to deter-
mine whether or not the study information has been
retained and understood. The research nurse will con-
sider the guidance in the Mental Capacity Act 2005
Code of Practice when assessing mental capacity. Those
who do wish to take part will be asked to give their for-
mal consent by signing the consent form. The written
informed consent process will be undertaken by the re-
search nurse who will be trained in Good Clinical Prac-
tice and the informed consent process.
Recruitment of patients from the community
Study entry criteria remain the same for this group of
participants except that they do not need to be resident
in a care home. Time points for data collection and the
outcome data items collected will be the same.Participant identification via Primary Care
The Clinical Research Network (South West Peninsula)
will support the identification and recruitment of re-
search active general practices (GPs) into the study.
Practices that decide to participate will be contacted by
the research nurse to discuss the requirements of the
study and the search criteria. GP staff will search for pa-
tients aged 65 years or older who have used oral steroids
for more than a month in the prior 12 month period.
Lists generated from the search will be screened for suit-
ability by a doctor at each participating practice and
unsuitable patients excluded, e.g. those with terminal ill-
ness, mental illness etc. A member of the practice staff
will send suitable patients an invitation letter on GP
headed paper, including a study reply form and reply-
paid envelope. Patients are asked to return the reply
form to the research team if interested in receiving more
information about the study. Patients that respond to
say that they are interested in receiving more informa-
tion will be contacted by a member of the research team
and an appointment made for the research nurses to
meet with the patient. The GP may send one follow-up
letter to all the patients originally invited with a sentence
advising that the letter should be ignored if they have
already responded. Patients who return the reply form
to the research team will then undergo the recruitment
process described below.
Participant identification via the NIHR Exeter Clinical
Research Facility
Potential participants may also be identified via the
“Exeter 10000” research volunteer bank managed by the
NIHR Exeter Clinical Research Facility (Exeter CRF).
The volunteer bank database will be searched by
authorised members of the Facility for volunteers aged
65 years and older who have used oral steroids for more
than a month in the prior 12-month period. A member
of the facility staff will send suitable volunteers an invita-
tion letter on Exeter CRF headed paper, including a
study reply form and reply-paid envelope. Volunteers
will be asked to return the letter (including the reply
form) to the Exeter 10000 team who will forward their
name to the research team if interested in receiving
more information about the study. Volunteers who re-
turn the reply form will then undergo the recruitment
process described below.
Community recruitment process
On receipt of a completed reply form, a research nurse
will telephone the patient or volunteer using the contact
details provided on the reply form, once the person has
had at least 24 h to read the study information. The re-
search nurse will ascertain potential eligibility by
explaining the full study entry criteria to the person. If
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tially eligible, and willing to take part, the research nurse
will arrange a visit at which eligibility will be confirmed
and informed consent obtained. Visits may be performed
at persons’ homes or at a local community hospital or
GP surgery if mutually convenient.
Informed consent, randomisation and baseline assessment
of community participants
At this initial visit, the research nurse will explain the
study and demonstrate a pair of the protective socks.
The written informed consent process will be under-
taken by a research nurse trained in GCP and the in-
formed consent process. Having reconfirmed eligibility,
those who do wish to take part will be asked to give
their formal consent by signing the consent form. Base-
line measures and randomisation will then be performed
as per protocol. On successful completion of this visit,
the REC approved GP letter will be posted to the partici-
pant’s GP, if the participant consents to their GP being
informed.
Participant retention
Plans to promote participant retention and complete the
follow-up include encouragement from the research
nurses who will be in regular telephone and face-to-face
contact with the participants, whether resident in a care
home or living independently in the community.
Intervention group
The protective socks are manufactured by Dermatuff
Limited. The socks are CE marked and are registered
with the Medicines and Healthcare products Regulatory
Authority (MHRA) as “Skin Tears Protection System
Wear”, a Class I Medical Device. Materials used in the
manufacture of the socks are in conformity with all rele-
vant and required standards including the ISO 10993
series evaluating biocompatibility of a medical device
prior to a clinical study.
The research nurse will carry a stock of protective
socks and, before leaving the care home, the research
nurse will visit those randomised to wear protective
socks to provide socks of the correct size. The socks are
available in a choice of grey or beige colour. The choice
of colour will be recorded by the research nurse. Three
pairs of socks will be provided to the care home for each
participant in the intervention group. The participants
will be able to keep these socks at the end of their par-
ticipation in the study.
The participants in the intervention group will be
asked to wear the protective socks during their waking
hours every day for a period of 16 weeks, starting from
the morning following the day they sign consent, which
will be designated as “Day 1.” Care home staff will beasked to encourage participants to wear the socks and to
assist them to put the socks on, if necessary. However, it
will be emphasised that if participants become unwilling
to wear the socks or want to take them off, they will be
free to make that choice. The participants should con-
tinue to wear their normal footwear during participation
in the study.
Participant diary
The participants in the intervention group will be given
the first of 16 weekly diaries at this visit and will be
asked by the research nurse to complete the diary on a
daily basis. The participants will be asked to use the
diary to record the extent to which they wear the socks
each day and the reasons for removing them (if applic-
able), plus any negative or positive comments about
wearing the socks. A new weekly diary will be provided
to the participant each week.
Control group
The participants in the control group will be managed
as usual. This includes any routine procedures to reduce
the risk of lacerations, but otherwise they will wear their
normal clothing. At the end of their participation, each
participant from the control group will be offered one
pair of socks to keep for their own use.
Outcome measures
The measures proposed for a future definitive trial will
be collected in this pilot study. The primary outcome of
a future trial will focus on skin-tear free days and the in-
cidence and severity of skin tears.
Procedure in the event of a skin tear injury
Care home staff or the community participant them-
selves will be asked to contact the research nurse by
telephone immediately on becoming aware of an injury
(i.e. as soon as possible on the day of the injury or the
following morning in the case of an overnight injury).
The research nurse will visit the resident or patient as
soon as practicable (within 1 to 2 working days) of being
contacted in order to collect the following:
 Date and approximate time of injury.
 Brief description of injury cause.
 Type of lower leg clothing and footwear worn at the
time of injury (including whether protective socks
were in place for participants in the intervention
group).
 Size of injury (length, width and total area using a
grid tracing method).
 Category of injury using the Payne-Martin and
STAR classifications (as described in Appendix).
 A photograph of the injury.
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the injury (dressing type, referral to external
healthcare professional such as GP, district nurse
and hospital emergency department).
The research nurse will inspect the wound for signs of
infection and will also check that the injury has been
noted in the care home records (in the case of care
home participants). Injured participants will complete
outcome measure questionnaires 7 days post-injury.
Primary outcome
A useful way to express the primary outcome measure is
the number of skin tear-free days. Each participant will
enter the study with no unhealed skin tear injuries and
will remain in the study (unless withdrawn prematurely)
for 112 days (i.e. 16 full weeks). Therefore, each partici-
pant has the potential to experience 112 skin tear-free
days. In the event of a skin tear injury, the number of
days from the date of injury until the date it is healed
will be subtracted from 112 to give the number of skin
tear-free days. A healed injury is defined as one which
has an absence of scab and full epithelial covering that
does not require continuance of dressing for absorption
of exudate (sometimes a dressing may be left on a healed
but delicate wound for a few days after healing). The
date of healing will be identified by the visiting research
nurse via wound inspection during regular, approxi-
mately weekly, visits and in collaboration with care
home staff as necessary. Participants who experience a
skin tear injury in week 16, or who have an injury dis-
covered at week 16, will continue to provide follow-up
information beyond that date and skin tear-free days will
be expressed as a proportion of the total follow-up time.
Secondary outcomes
Skin tear assessments
There is no universally accepted classification system for
the assessment of skin tears. Payne and Martin devel-
oped the first classification system in 1990, and this was
updated in 1993 [1]. Problems associated with inter-
rater reliability testing of the Payne and Martin classifi-
cation system, and its poor utility in Australia, led to a
study that resulted in the Skin Tear Audit Research
(STAR) Classification System. The STAR Classification
System is commonly used in Australia, with evidence of
implementation reported within the UK [30].
In the main trial, skin lacerations will be measured in
centimetres (length, breadth and area) and graded either
according to Payne-Martin categories or the STAR Skin
Tear Classification System. The photographs will inform
an assessment of the reliability of the reported grading
of the injury and will be performed by a tissue viability
nurse specialist blinded to allocation.Skin tear assessments will be performed upon learning
of an injury, within 24 h if possible.Other secondary outcome measures
 Standardised measure of health status (EQ-5D-5L):
collected at baseline, 16 weeks and in the event of a
skin tear injury.
 Assessment of capability (ICECAP-O): collected at
baseline, 16 weeks and in the event of a skin tear
injury.
 Assessment of fear of falling (Short FES-I): Collected
at baseline, 16 weeks and in the event of a skin tear
injury.
 Disease-specific quality of life measured by Cardiff
Wound Impact Schedule: Collected in the event of a
skin tear injury and at 16 weeks (from participants
who have had a skin tear).
 Adverse events caused by the socks.
 Health care resource use: collected in the event of a
skin tear injury.
 Outcome measures for the pilot study are:
 Recruitment rate for homes.
 Proportion of participants (home residents) eligible.
 Recruitment rate for participants.
 Attrition and loss to follow up.
 Ascertainment of injuries.
 Completion and completeness of study
questionnaires.
 Estimates of the distribution of outcome measures.
 Feasibility of the workload.
 Acceptability of the intervention to participants.
 Acceptability of study participation to participants.Withdrawal and dropout
The participants may withdraw their consent at any
time. The participants will be advised that they do not
have to provide a reason for withdrawing their consent
but if they are willing to provide a reason when asked by
the research nurse the reason will be recorded. Standard
care will not be affected by a participant’s decision to
withdraw from the study. Data collected prior to with-
drawal will be included in the study analysis unless a
participant specifically requests that their data are re-
moved from the database. If a participant is adjudged to
have lost mental capacity during the 16-week study
period, that participant will be withdrawn from the
study. Data already collected with consent will be
retained and used in the study. No further data will be
collected or any other study procedures carried out on
or in relation to the participant. It is anticipated that
some participants allocated to the socks group may dis-
continue wearing the socks but will still be happy to fill
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the event of a skin tear.Adverse and serious adverse events
In the STOPCUTS study, adverse events which are not
serious and not related to study participation will not be
recorded or reported. Adverse events which are serious
and/or related to study procedures/intervention will be
recorded. Multiple symptoms should be recorded as sep-
arate events. The events will be reported to the Chief In-
vestigator, Sponsor and the Peninsula Clinical Trials
Unit on a designated report form which will capture the
research nurse’s opinion on the relatedness of the event
to study procedures/intervention, and also on the ex-
pectedness of the event. Adverse reactions to the socks
are expected to be uncommon. The following list of po-
tential symptoms will be used as a reference when asses-
sing the expectedness of adverse device effects.
 Allergic-type skin reaction.
 Miliaria.
 Chafing.
 Excessive sweating under the socks.
 Skin tears or bruising caused by putting on or
removing the socks.
 Pain, discomfort, numbness, swelling or any other
condition caused by socks which are too tight.
 Falls or other accidents caused by slipping or
tripping as a result of wearing the socks.
Accumulative summaries of adverse reactions will be
reviewed periodically by the Trial Steering Committee.Data handling
Participant numbering
Each participant will be allocated a unique four-digit
identification number. Each participant will be identified
in all study-related documentation by his/her study
number and initials. A record of names linked to partici-
pants’ study numbers will be maintained by the research
nurse and stored securely for administrative purposes.Data capture and transfer
Data will be recorded on study-specific case report
forms (CRFs) by the research nurse and directly into
questionnaire booklets and diaries by participants. Pho-
tographs taken by research nurses will be saved, trans-
ferred and stored according to the Royal Devon and
Exeter Hospital’s local policy. The images will be stored
securely on the hospital system in accordance with data
protection regulations.Data entry
Completed paper CRF’s will be checked and signed by
the research nurse before being sent to the clinical trials
unit. Original paper CRF pages, questionnaire booklets
and diaries will be posted to the trials unit at agreed
time points for double-data entry onto a password-
protected database in accordance with the trials unit
standard operating procedures (SOP’s). Research nurses
will also have the option of entering CRF data at agreed
time points directly onto the study database via the
study website. These data will not be double entered.
Forms will be tracked using a Web-based study manage-
ment system. Double-entered data will be compared for
discrepancies using a stored procedure. Discrepant data
will be verified using the original paper data sheets.
Data confidentiality
The research nurses will ensure that participants’ ano-
nymity is maintained on all documents and images. Data
will be collected and stored in accordance with the Data
Protection Act, 1998. Within the trials unit, anonymised
paper-based study data will be stored in locked filing
cabinets within a locked office. Electronic records will be
stored in a Structured Query Language (SQL) server
database, stored on a restricted access, secure server
maintained by Plymouth University. The website will be
encrypted using Secure Sockets Layer data encryption
(SSL). Direct access to the study data will be restricted
to members of the study team, the Sponsor and the Pen-
insula Clinical Trials Unit. Access to the database will be
overseen by the trials unit data manager and trial man-
ager. Copies of study data retained at study sites (i.e.
care homes) will be securely stored for the duration of
the study prior to archiving.
Archiving
Following completion of study data analysis, the sponsor
will be responsible for archiving the study data and es-
sential documentation in a secure location for a mini-
mum period of 5 years after the end of the study. No
study-related records should be destroyed unless or until
the sponsor gives authorisation to do so.
Statistical methods
The study will be analysed using the statistical package
SPSS v. 20 (IBM Corp, New York). Missing data will be
investigated and the proportion missing will be recorded
but are expected to be minimal. Multiple imputation
methods or any specific imputation methods recom-
mended by the authors of the questionnaire will be used
to obtain realistic estimates of scores for future planning
of questionnaire usefulness. All the questionnaires con-
cerning acceptability of the socks will be scored and sum-
marised using appropriate measures of central tendency
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marised in a similar way. Agreement on wound grading
between research nurses and a blinded tissue viability ex-
pert (AK) will be assessed from anonymised photographs
using weighted kappa. Numbers of eligible residents, re-
cruitment, attrition and loss to follow-up (as per the Con-
solidated Standards of Reporting Trials (CONSORT)
diagram) will be reported as proportions, confidence inter-
vals will be reported wherever appropriate. The main ana-
lysis will describe skin tear-free days and the incidence
and severity of skin lacerations in each group.
The pilot study will determine the feasibility of how
the outcomes can be measured. These will be used to in-
form the sample size of the full-scale randomised con-
trolled trial. In that trial, we intend to compare the
incidence of skin damage between the two groups on an
intention-to-treat basis and the size of any wounds by
objective assessors (research nurses). The clustering ef-
fects of homes will be an issue in the analysis of a future
definitive randomised controlled trial, and sample size
inflation will need to be considered for a mixed effects
model with “homes” as a random effect.
Economic evaluation
The economic evaluation in the future definitive trial
will estimate the additional NHS cost per quality-
adjusted life years (QALY) gained by the use of these
protective socks. QALY estimation will be based on the
EuroQol descriptive system (EQ-5D-5L) collected at
baseline and at 16 weeks for all participants, and at
7 days after a participant incurs a skin tear injury to the
leg. In the pilot study, a note will be made of how many
of the participants have difficulties understanding or
completing EQ-5D-5L to assess whether there is a need
to include proxy assessment in the design of the main
trial.
The study will collect data on the resources used by
the care homes, GPs or healthcare professionals and the
NHS in the management of skin tears. The primary
source of these data will be the participants’ medical re-
cords of their normal procedures, visits from district or
tissue viability nurses, visits to and from GP’s and any
care needs arising from adverse events. The pilot study
will assess whether care home records and or partici-
pants’ medical notes are adequate to describe resource
use in a costable format.
Qualitative interviews and focus groups
Semi-structured qualitative interviews with ten partici-
pants from each arm of the study will be conducted at
the end of the follow-up period by an independent re-
searcher. These will include a range of participants with
varying degrees of mobility across the areas. Experiences
of using the protective socks, their acceptability and/ortaking part in the study will be captured. The partici-
pants will be selected using purposive sampling in-
formed by research nurse data on their clinical progress
with regard to skin tears, perceived protection from
knocks and falls, withdrawals, adverse events and any
problems with the skin-tear and/or questionnaire data
collection process. Interviews will be digitally recorded
and transcribed with the main themes identified using
content analysis.
Two focus groups will be held to explore the useful-
ness of the protective socks. These will include profes-
sionals from the Tissue Viability Service and care home
staff with experience of participants assigned to the
intervention arm of the study. Holding two focus groups
provides easy access for staff of care homes across the
large geographical area of the pilot trial.Quality control
The research nurse will check completed case report
forms for missing data or obvious errors before the
forms are sent to the trials unit. Data will be monitored
centrally for quality and completeness, and every effort
will be made to recover data from incomplete forms
where possible. The data manager at the trials unit will
oversee data tracking and data entry and initiate pro-
cesses to resolve data queries where necessary, and the
trial manager will devise a monitoring plan specific to
the study which will include both central monitoring
strategies and study site visits if appropriate.
Participating care homes will be required to permit the
trial manager or deputy or representative of the sponsor
to undertake study-related monitoring to ensure compli-
ance with the approved study protocol and applicable
standard operating procedures, providing direct access
to source data and documents as requested. All study
procedures will be conducted in compliance with the
protocol and according to the principles of the Inter-
national Conference on Harmonisation Good Clinical
Practice (ICH GCP). Procedures specifically conducted
by the clinical trials unit (e.g. randomisation, data man-
agement, study management and study monitoring) will
be conducted in compliance with the trials unit’s stand-
ard operating procedures.
A trial management team meets regularly to discuss
the progress of the trial and address any issues that arise.
A Trial Steering Committee, with an independent chair,
independent clinician and independent statistician meets
approximately every 6 months to oversee the conduct
and safety of the trial.Ethics
The study will be performed subject to approval by the
Cornwall and Plymouth NRES Research Ethics Committee,
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and local Research and Development approval.
Discussion
Skin tears are the second most prevalent injury type in
care homes after pressure ulcers [15] and a cause of con-
siderable pain, misery and lost confidence in older
people and those with fragile skin due to long-term use
of medications such as steroids. They also represent a
considerable cost to the NHS. Existing measures to pre-
vent skin tears have limited effectiveness in this suscep-
tible population [27,28]. This pilot trial and any future
definitive trial arising from it will focus on this important
area of healthcare. This pilot will address the uncer-
tainties in planning a future definitive randomised con-
trolled trial.
The areas of uncertainty to be addressed are typical in
a study of this nature, the feasibility of recruitment (of
care homes, general practices and of individual partici-
pants), the suitability of outcome measure assessments
and their timing and the distribution of variables (and
therefore the number of participants needed in a full de-
finitive trial of effectiveness). In particular, it will focus
on the acceptability of the socks. Preliminary work and
early patient and public involvement indicated that they
might not be aesthetically pleasing to participants because
of their current limited colour range (charcoal grey or tan)
and perceived thickness. Doubts have also been raised
about comfort and fitting as there are currently only four
sizes available (small, medium, medium-wide and large).
Other sizes and colours could be manufactured in the fu-
ture. We also don’t know whether the socks can be worn
and tolerated during the different seasons of the year. We
hope to tease these issues out in the qualitative interviews
and the daily diaries.
One possible weakness of the pilot study design is the
potential for contamination because the socks are com-
mercially available on the Internet. Participants and/or
their relatives or carers will know of the existence of
Dermatuff socks, having read about them in the study Par-
ticipant Information Sheet. It would not be difficult to ob-
tain some socks for themselves if they have originally been
assigned to the control group and decide that they need
some. In primary care recruitment, it is also possible that
GPs may recommend Dermatuff socks to their patients in
the control group, hence contaminating the sample. Any
contamination that occurs in this pilot will be recorded,
and the information will be used in the planning of a fu-
ture trial. Cluster randomisation would not prevent this
direct contamination, but it might minimise the “indirect
contamination” caused by control group participants see-
ing intervention group participants wearing the socks, and
altering their own behaviour to better protect their legs —
by perhaps being more careful how they move around ortaking other protective measures — such as wearing their
own leg-wear more often.
A particular strength of this trial is that it is taking
place partly in care homes, which represent an under-
researched population of older people. This is thought
to be a difficult area for researchers to tackle because of
perceived problems with access to residents and the
prevalence of dementia in this population, which limits
the number eligible to take part in research. Sadly, older
people with dementia are at even greater risk of skin
tears than those without it [8]. Furthermore, care home
representatives involved in the planning of this trial have
informed us that people with dementia are much more
at risk of receiving skin tears. The Mental Capacity Act
2005 states that for people lacking capacity to consent,
any research that they may be permitted to take part in
must be connected with an impairing condition affecting
such a person or its treatment. “Impairing condition”
means a condition which is (or may be) attributable to,
or which causes or contributes to (or may cause or con-
tribute to), the impairment of, or disturbance in the func-
tioning of, the mind or brain. It could be argued that
increased skin tear prevalence amongst people with de-
mentia is attributable to the condition, and that any efforts
to reduce their incidence should be pursued. If this were
the case, given the high prevalence of dementia in care
homes, a future trial might be conducted entirely within
the care home environment with appropriate consultation
with carers, as the Mental Capacity Act 2005 requires.
Dermatuff socks offer hope of some protection from
skin tears when very few other measures have worked,
and this pilot will go some way to indicating whether it is
worth carrying out a full scale definitive trial in the future
to determine their effectiveness and cost effectiveness.Trial status
The STOPCUTS trial has been designed as a pilot, par-
allel group randomised controlled trial of effectiveness.
The initiation took place at the Royal Devon and Exeter
Hospital, Devon, UK in July 2013 after approval by the
research ethics committee with two subsequent amend-
ments to refine the recruitment process. The trial com-
menced in July 2013. Recruitment is ongoing and is
scheduled to end in October 2014. Data collection is
scheduled to continue until February 2015 and results
will be analysed in July 2015.Appendix
Skin tear categorisation
Payne-Martin classification
 Category I: Skin tear without loss of tissue. The
epidermal flap either completely covers the dermis
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margin
o Sub category Ia: Linear type
o Sub category Ib: Flap type
 Category II: Skin tear with partial tissue loss
o Sub category IIa: Scant tissue loss (25% or less)
o Sub category IIb: Moderate to large loss of
tissue (>25% loss of the epidermal flap)
 Category III: Skin tear with complete tissue loss.
STAR Skin Tear Classification System
 Category 1a: A skin tear where the edges can be
realigned to the normal anatomical position (without
undue stretching) and the skin or flap colour is not
pale, dusky or darkened.
 Category 1b: A skin tear where the edges can be
realigned to the normal anatomical position (without
undue stretching) and the skin or flap colour is pale,
dusky or darkened.
 Category 2a: A skin tear where the edges cannot be
realigned to the normal anatomical position and the
skin or flap colour is not pale, dusky or darkened.
 Category 2b: A skin tear where the edges cannot be
realigned to the normal anatomical position and the
skin or flap colour is pale, dusky or darkened.
 Category 3: A skin tear where the skin flap is
completely absent.
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